Remdesivir for the Treatment of SARS-CoV-2

SARS-CoV-2, also known as 2019 Novel Coronavirus, is a coronavirus identified as the cause of an outbreak of respiratory illness in Wuhan, China on 31 December 2019. Based on our extensive experience in drug discovery, Creative Biolabs has developed the unique platforms against the SARS-CoV-2.

SARS-CoV-2

Coronaviruses are a large family of viruses common in a variety of animals. Sometimes, these coronaviruses can infect humans and then spread between humans, such as SARS, MERS, and the SARS-CoV-2. Similar to influenza and other respiratory pathogens, the people-to-people spread occurs via respiratory droplets from the patients' coughs or sneezes and the patients might be most contagious when they are most symptomatic. The genetic analyses showed that SARS-CoV-2 emerged from a virus related to SARS. The possible symptoms of SARS-CoV-2 include fever, cough, and shortness of breath. Based on the incubation period of MERS viruses, these symptoms of SARS-CoV-2 may appear in 2-14 days after exposure. In order to avoid the growing public health threat posed by this new coronavirus, it is urgent to develop the antiviral drugs against SARS-CoV-2.

Remdesivir for The Treatment of SARS-CoV-2

Remdesivir, with the development code GS-5734, is a novel nucleotide analog prodrug presenting broad-spectrum antiviral activity. It has been recognized as a promising antiviral drug against a wide array of RNA viruses (including SRAS and MERS) infection in a series of animal models. As an adenosine analogue, the remdesivir incorporates into nascent viral RNA chains and results in pre-mature termination. In addition, the study has shown that remdesivir inhibits virus infection efficiently in the human liver cancer Huh-7 cells, which is sensitive to SARS-CoV-2. The assay data showed that EC90 value of remdesivir against SARS-CoV-2 in Vero E6 cells was 1.76 μM, which means that its working concentration is likely to be achieved in nonhuman primate (NHP). In conclusion, remdesivir is highly effective in the control of SARS-CoV-2 infection in vitro. In response to the SARS-CoV-2 outbreak, Creative Biolabs now can provide the further assays for our clients and develop new antiviral drugs against SARS-CoV-2.

Drug Discovery Services

Creative Biolabs has built a one-stop drug discovery platform for the drug development of SARS-CoV-2. Our drug discovery services include:

• Target identification and validation
• Hit identification
• Hit to lead
• Lead optimization
• IND-Enabling

As a professional service provider for drug discovery, Creative Biolabs provides a variety of related services. If you are interested in our services, please do not hesitate to contact us for more details.

For Research Use Only. We do not provide direct services or products for patients.